Last reviewed · How we verify
Meningococcal A (control)
This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup A polysaccharide capsule.
This vaccine stimulates the immune system to produce antibodies against Neisseria meningitidis serogroup A polysaccharide capsule. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup A.
At a glance
| Generic name | Meningococcal A (control) |
|---|---|
| Sponsor | International Vaccine Institute |
| Drug class | polysaccharide vaccine |
| Target | Neisseria meningitidis serogroup A capsular polysaccharide |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The meningococcal A vaccine contains purified polysaccharide antigen from the serogroup A capsule of Neisseria meningitidis. Upon administration, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies (primarily IgG) that bind to the bacterial capsule and facilitate complement-mediated bactericidal killing and opsonophagocytosis. This provides immunity against invasive meningococcal disease caused by serogroup A strains.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup A
Common side effects
- Injection site pain or erythema
- Fever
- Headache
- Myalgia
Key clinical trials
- Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection (PHASE2)
- Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections (PHASE3)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
- R21/Matrix-M in African Children Against Clinical Malaria (PHASE3)
- A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104 (PHASE1)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (PHASE2)
- Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meningococcal A (control) CI brief — competitive landscape report
- Meningococcal A (control) updates RSS · CI watch RSS
- International Vaccine Institute portfolio CI